跳至主要内容
临床试验/NCT05180396
NCT05180396已完成不适用

A Multicenter, Cross-sectional Study Evaluating the Symptoms, Clinical Follow-ups, Problems Encountered During the Course of the Disease, Disease Awareness and Treatment Compliance of Heart Failure Patients - AWARENESS HF-PD(Patient Diary)

AstraZeneca Turkey3 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2021年3月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
200
试验地点
3
主要终点
Disease Information

研究概览

简要总结

The AWARENESS HF-PD is a cross-sectional, multicenter, survey-based study. Cases who were admitted to the outpatient clinic and hospitalized with the diagnosis of Heart Failure (Acute and Chronic) will be included in the study.

详细描述

Data entry personnel to be assigned at the centers throughout the study will apply a questionnaire consisting of different questions to patients referred to them by clinicians with the diagnosis of HF. In addition, clinical features of HF from the current file of the cases (NYHA, comorbid conditions, comorbid diseases, blood pressure, heart rate, latest biochemistry (BNP/NTproBNP if available), hematology test results, most recent ECG, most recent echocardiography , coronary angiography report, if any) will be recorded. No additional examination/procedure will be performed for the study, only the data of the examinations requested by the clinician in routine clinical practice will be entered. A total of 200 patients from 3 centers will be included in this study over a six-month period.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female patients aged 18 and over
  • Patients diagnosed with acute or chronic heart failure
  • Patients who agreed to participate in the study

排除标准

  • Patients who stated that they did not agree to participate in the study
  • Patients who were not diagnosed with Heart Failure or whose diagnosis was changed or not confirmed during the index application

结局指标

主要结局

Disease Information

时间窗: 6 months

At the end of the six-month recruitment period disease information, treatment compliance, and awareness assessment will be performed on all included patients.

Demographics

时间窗: 6 months

At the end of the six-month recruitment period, demographic, symptoms, clinical follow-up status, d will be performed on all included patients.

次要结局

  • HF Percutaneous Intervention / Operation History (CRT, ICD, CRT-DI, Pacemaker, PKG, CABG and Heart Valve Operations)(6 months)
  • HF Risk Factors (BMI, Diabetes, Hypertension, HLP, Tobbaco Use, CV Hereditary, Menapause, MI History and History of CMP in family)(6 months)
  • HF ECHO Results (EF, LA, SID, Mitral Defficiency, SPAB, DID, Septum, SEG Muscle Weakness, Trial Defficiency)(6 Months)
  • HF Comorbidities (CAD, AF, COPD, CRF, Anemia, Iron Defficiency, Hypo- Hypertiroidy, OSAS)(6 months)
  • HF Laboratory Results (Glucose, BUN, Creatinine, GFR, Sodium, Potassium, Nt-ProBNP, ALT, AST, ALP, HS-CRP, cTN, Hemoglobine, WBC, Ferritine, TSAD, LDL, tryglyceride, ST3, GGT, INR, ST4)(6 months)

研究者

发起方
AstraZeneca Turkey
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验

A Study on Disease Awareness and Treatment... | 临床试验